Stephanie Pilkington Partner

Stephanie Pilkington
  • Personal profile
  • News and publications

Personal profile

PhD, MA, European Patent Attorney, Chartered Patent Attorney, Intellectual Property Litigation Certificate 

Stephanie’s areas of specialism include: molecular biology; biochemistry; drug screening; personalised and stratified medicine; diagnostic and prognostic markers for cancer and other diseases; diagnostic assays; therapeutic strategies; microarray and nucleic acid technology; medical devices. She has particular expertise in filing and prosecution strategy; life cycle management; SPCs (supplementary protection certificates); oppositions; freedom to operate; due diligence investigations, technology/knowledge transfer; start-ups/spin-outs through to established international corporations; early stage research through to mature products and portfolios. 

Stephanie has extensive experience of both prosecution and oppositions at the EPO and regularly advises on filing and prosecution strategy as well as oppositions and due diligence investigations. She has also advised on SPC strategy in relation to small molecules and biologics, and has prosecuted SPC applications in the UK and elsewhere.  

Stephanie read Natural Sciences (Biochemistry) at Trinity College, Cambridge, before completing a PhD in Molecular Biology at the Medical Research Council's Laboratory of Molecular Biology (LMB) in Cambridge.  

After continuing her research at the LMB and serving as a Research Fellow at Lucy Cavendish College, Cambridge, she worked for Fisons Pharmaceuticals, then Astra AB, as a research biochemist. Stephanie joined Potter Clarkson in 1997 and became a Partner in 2004. In 2014, she was appointed a member of the Board of Management. Her experience is wide-ranging and includes extensive experience in advising SMEs and academic technology transfer departments. 

Stephanie is a fellow of the Chartered Institute of Patent Attorneys and a CIPA Life Sciences Committee member. She is an active contributor to discussions and policy submissions through the CIPA Life Sciences Committee and subcommittees, for example relating to SPCs, and has been named as one of the 2017 WIPR Leaders.